Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience.

ABSTRACT:

Background

Drug-eluting stents are widely used in coronary artery intervention. However, vessel caging and very late thrombotic events are of persistent and substantial concern. Bioresorbable vascular scaffolds (BVS) were developed to deliver vascular reparative therapy, by eliminating permanent mechanical restraint. However, data regarding its clinical performance is lacking.

Methods

After the BVS implantation procedure received national approval in May 2014, patients receiving BVS implantation until November 2014 in National Taiwan University Hospital (NTUH) were enrolled. Clinical variables, angiographic data, procedural details, and follow-up information were collected and compared with those receiving BVS at NTUH as part of the global ABSORB EXTEND trial.

Results

SUBMITTER: Liang HW 

PROVIDER: S-EPMC5445242 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature